{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:07:55Z","timestamp":1760573275851,"version":"build-2065373602"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04233-y","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T15:32:43Z","timestamp":1760455963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence, demographic characteristics and clinical profile of metabolic dysfunction-associated fatty liver disease among adult patients attending tertiary hospitals in Dodoma, Tanzania. a cross-sectional study"],"prefix":"10.1186","volume":"25","author":[{"given":"Francis","family":"Msagati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baraka","family":"Alphonce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Sindato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"4233_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.04.015","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Wong G, Anstee QM, Henry L. The global burden of liver disease. Clin Gastroenterol Hepatol. 2023. https:\/\/doi.org\/10.1016\/j.cgh.2023.04.015.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4233_CR2","doi-asserted-by":"publisher","first-page":"103584","DOI":"10.1016\/j.ebiom.2021.103584","volume":"72","author":"F Bril","year":"2021","unstructured":"Bril F. EBioMedicine what the new de Fi nition of metabolic Dysfunction-Associated fatty liver disease (MAFLD) left behind: genetically acquired fatty liver disease. EBioMedicine. 2021;72:103584.","journal-title":"EBioMedicine"},{"key":"4233_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s13105-023-00954-4","author":"P Sangro","year":"2023","unstructured":"Sangro P, De M, Al\u00e1ez T, Sangro B, Avola DD. Metabolic dysfunction \u2013 associated fatty liver disease (MAFLD): an update of the recent advances in Pharmacological treatment. J Physiol Biochem. 2023. https:\/\/doi.org\/10.1007\/s13105-023-00954-4.","journal-title":"J Physiol Biochem"},{"key":"4233_CR4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/CM9.0000000000002089","volume":"135","author":"SDW Bae","year":"2022","unstructured":"Bae SDW, George J, Qiao L. From MAFLD to hepatocellular carcinoma and everything in between. Chin Med J (Engl). 2022;135:547\u201356.","journal-title":"Chin Med J (Engl)"},{"key":"4233_CR5","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"K Cusi","year":"2022","unstructured":"Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, et al. American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-Sponsored by the American association for the study of. Endocr Pract. 2022;28:528\u201362.","journal-title":"Endocr Pract"},{"key":"4233_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-gomez M, et al. Expert opinion A new de Fi nition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202\u20139.","journal-title":"J Hepatol"},{"key":"4233_CR7","doi-asserted-by":"crossref","unstructured":"Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. 2020;:1\u201317.","DOI":"10.21037\/tgh.2019.09.08"},{"key":"4233_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fgstr.2025.1506032","volume":"4","author":"EM Sindato","year":"2025","unstructured":"Sindato EM, Kajogoo VD, Ngajilo G, Degu WA, Khan Z, Mlawa G. Prevalence and risk factors of metabolic-associated fatty liver disease in sub-Saharan africa: a systematic review and meta-analysis. Front Gastroenterol. 2025;4:1\u20139.","journal-title":"Front Gastroenterol"},{"key":"4233_CR9","doi-asserted-by":"crossref","unstructured":"Guan L, Zhang X, Tian H, Jin X, Fan H, Wang N et al. Prevalence and risk factors of metabolic- \u00ad associated fatty liver disease during 2014\u20132018 from three cities of Liaoning province: an epidemiological survey. 2022;:1\u20139.","DOI":"10.1136\/bmjopen-2020-047588"},{"key":"4233_CR10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2147\/DMSO.S283595","volume":"14","author":"D Zubery","year":"2021","unstructured":"Zubery D, Kimiywe J, Martin HD. Prevalence of overweight and obesity, and its associated factors among health-care workers, teachers, and bankers in Arusha city, tanzania. Diabetes. Metab Syndr Obes. 2021;14:455\u201365.","journal-title":"Metab Syndr Obes"},{"key":"4233_CR11","unstructured":"Malindisa EK, Balandya E, Mashili F, Iddi S, Njelekela M. The magnitude of type 2 diabetes mellitus and cardiovascular disease risk factors among young adults in urban settings: a cross-sectional survey in mwanza, Tanzania. Pan Afr Med J. 2022;42(19)."},{"key":"4233_CR12","doi-asserted-by":"crossref","unstructured":"Katatwire DD, Meremo A. Prevalence of and factors associated with uncontrolled hypertension among patients with early chronic kidney disease attending tertiary hospitals in dodoma, Tanzania : a cross- \u00ad sectional study. 2023;:1\u20139.","DOI":"10.21203\/rs.3.rs-2146111\/v1"},{"key":"4233_CR13","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1161\/CIRCULATIONAHA.121.054602","volume":"146","author":"PK Whelton","year":"2022","unstructured":"Whelton PK, Carey RM, Mancia G, Kreutz R, Bundy JD, Williams B. Harmonization of the American college of cardiology\/american heart association and European society of cardiology\/european society of hypertension blood pressure\/hypertension guidelines: comparisons, reflections, and recommendations. Circulation. 2022;146:868\u201377.","journal-title":"Circulation"},{"key":"4233_CR14","first-page":"1","volume":"2017","author":"E Yorke","year":"2017","unstructured":"Yorke E, Atiase Y, Akpalu J, Sarfo-Kantanka O, Boima V, Dey ID. The bidirectional relationship between tuberculosis and diabetes. Tuberc Res Treat. 2017;2017:1\u20136.","journal-title":"Tuberc Res Treat"},{"key":"4233_CR15","unstructured":"C.Riddle M 2019. American Diabetes Association Standards of Medical Care in Diabetesd 2019. ada 2019."},{"key":"4233_CR16","unstructured":"Simelane NN, Nontobeko. Et Al. 2019;:1\u201314."},{"key":"4233_CR17","doi-asserted-by":"crossref","unstructured":"Diaby A, Zahe KYAS, Me\u00eft\u00e9 A, Traor\u00e9 M, Abodo JR, Kati-Coulibaly S. State of Knowledge on the Metabolic Syndrome and NASH in the Ivorian Population: Case of People Attending the Diabetology Endocrinology Service of the University Hospital Center (CHU) of Yopougon(Abidjan, C\u00f4te d\u2019Ivoire). Food Nutr Sci. 2023;14:657\u201369.","DOI":"10.4236\/fns.2023.147043"},{"key":"4233_CR18","doi-asserted-by":"crossref","unstructured":"Chen Y, Li H, Li S, Xu Z, Tian S, Wu J et al. Prevalence of and risk factors for metabolic Dysfunction-Associated fatty liver disease in an urban population in china: a cross \u2013 sectional comparative study. BMC Gastroenterol ogy. 2021; 21:1\u201312.","DOI":"10.1186\/s12876-021-01782-w"},{"key":"4233_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jfma.2023.07.010","volume":"123","author":"KL Cheng","year":"2024","unstructured":"Cheng KL, Wang SW, Cheng YM, Hsieh TH, Wang CC, Kao JH. Prevalence and clinical outcomes in subtypes of metabolic Dysfunction-Associated fatty liver disease. J Formos Med Assoc. 2024;123:36\u201344.","journal-title":"J Formos Med Assoc"},{"key":"4233_CR20","first-page":"e573","volume":"20","author":"J Liu","year":"2022","unstructured":"Liu J, Ayada I, Zhang X, Wang L, Li Y, Wen T, et al. Estimating global prevalence of metabolic Dysfunction-Associated fatty liver disease in overweight or obese adults. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2022;20:e573\u201382.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"4233_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/life11020143","volume":"11","author":"Y Sumida","year":"2021","unstructured":"Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, et al. FIB-4 first in the diagnostic algorithm of metabolic-dysfunction- associated fatty liver disease in the era of the global metabodemic. Life. 2021;11:1\u201320.","journal-title":"Life"},{"key":"4233_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2022.934225","volume":"13","author":"W Wen","year":"2022","unstructured":"Wen W, Li H, Wang C, Chen C, Tang J, Zhou M, et al. Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis. Front Endocrinol (Lausanne). 2022;13:1\u20138.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4233_CR23","doi-asserted-by":"crossref","unstructured":"Yuan Q. Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease among 73, 566 Individuals in Beijing, China. 2022.","DOI":"10.3390\/ijerph19042096"},{"key":"4233_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-024-64301-3","volume":"14","author":"J Imai","year":"2024","unstructured":"Imai J, Takashimizu S, Suzuki N, Ohshinden K, Sawamoto K, Mishima Y, et al. Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD. Sci Rep. 2024;14:1\u20137.","journal-title":"Sci Rep"},{"key":"4233_CR25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3748\/wjg.v29.i1.126","volume":"29","author":"MS Jeeyavudeen","year":"2023","unstructured":"Jeeyavudeen MS, Khan SKA, Fouda S, Pappachan JM. Management of metabolic-associated fatty liver disease: the diabetology perspective. World J Gastroenterol. 2023;29:126\u201343.","journal-title":"World J Gastroenterol"},{"key":"4233_CR26","doi-asserted-by":"crossref","unstructured":"Ge X, Lu J, Yu C, Guo W, Tian T, Xu X et al. Associations between active, passive smoking and the risk of nonalcoholic fatty liver disease. 2024;12:113\u20138.","DOI":"10.14218\/JCTH.2023.00165"},{"key":"4233_CR27","doi-asserted-by":"crossref","unstructured":"Sogabe M, Okahisa T, Kurihara T, Kagawa M, Ueda H, Kawaguchi T et al. Comparison of the role of alcohol consumption and qualitative abdominal fat on NAFLD and MAFLD in males and females. Sci Rep. 2022;12:1\u201312.","DOI":"10.1038\/s41598-022-20124-8"},{"key":"4233_CR28","first-page":"12","volume":"6","author":"YH Yeo","year":"2023","unstructured":"Yeo YH, Zhu Y, Arab JP, Ni W, Xu X, Shi J, et al. Alcohol Intake Thresholds among Individuals Steatotic Liver Disease. 2023;6:12\u20135.","journal-title":"Alcohol Intake Thresholds among Individuals Steatotic Liver Disease"},{"key":"4233_CR29","doi-asserted-by":"crossref","unstructured":"Paci A, Disease L. Metabolic fatty liver syndromes: where do we stand in 2024 ? 2024;39:613\u20134.","DOI":"10.1111\/jgh.16507"},{"key":"4233_CR30","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1111\/liv.15055","volume":"41","author":"A Sugiyama","year":"2021","unstructured":"Sugiyama A, Kurisu A, Ouoba S, Bunthen E, Ko K, Rakhimov A, et al. Relationship between drinking frequency and fatty liver prevalence or incidence in Japanese undergoing health checkup in 2008\u20132019. Liver Int. 2021;41:2914\u201323.","journal-title":"Liver Int"},{"key":"4233_CR31","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1159\/000515445","volume":"37","author":"E Roeb","year":"2021","unstructured":"Roeb E. Excess body weight and metabolic (Dysfunction)-Associated fatty liver disease (MAFLD). Visc Med. 2021;37:273\u201380.","journal-title":"Visc Med"},{"key":"4233_CR32","doi-asserted-by":"crossref","unstructured":"Chen K. Association of leisure sedentary behavior and physical activity with the risk of nonalcoholic fatty liver disease: a two-sample Mendelian randomization study. 2023; June:1\u201310.","DOI":"10.3389\/fnut.2023.1158810"},{"key":"4233_CR33","first-page":"1","volume":"June","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhao Q, Yang J, Wang Y, Deng L, Xieyire H, et al. Joint association of sleep quality and physical activity with metabolic dysfunction-associated fatty liver disease: a population-based cross-sectional study in Western China. Nutr Diabetes. 2024;June:1\u20138.","journal-title":"Nutr Diabetes"},{"key":"4233_CR34","unstructured":"Mukherji A, Bailey SM, Staels B, Baumert TF. Abstract: :1\u201325."}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04233-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04233-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04233-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T02:16:33Z","timestamp":1760494593000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04233-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4233"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04233-y","relation":{},"ISSN":["1471-230X"],"issn-type":[{"type":"electronic","value":"1471-230X"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"Conceptualization:\u00a0Dr. Francis Msagati, Dr. Emmanuel Sindato, Dr. Baraka Alphonce.\u00a0Data curation:\u00a0Dr. Francis Msagati.\u00a0Methodology:\u00a0Dr. Francis Msagati, Dr. Baraka Alphonce.\u00a0Supervision:\u00a0Dr. Emmanuel Sindato, Dr. Baraka Alphonce","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"This study followed the ethical criteria mentioned in the Declaration of Helsinki. The Directorate of Research and Publications provided ethical clearance (reference number: MA.84\/261\/02\/\u2018A\u2019\/66\/19), and the Vice Chancellor\u2019s office at the University of Dodoma approved the work. The respective centers received permission to perform the study. Patients were advised that their participation was voluntary and that they might withdraw at any time. To ensure privacy and confidentiality, patients\u2019 identities were replaced with identification numbers. Patients might exit the study at any time they wanted. It is worth mentioning that their choice to participate had no bearing on the quality of service they received, and individuals who were discovered to have MAFLD were informed. The consent that was obtained from all of the participants was informed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"734"}}